採用
Sarepta
Sarepta
Genetic medicine company
Gene Therapy
Drug Development
Clinical Research
Molecular Biology
Biostatistics
募集中のポジション
0件のポジション
現在募集中のポジションはありません
製品・サービス
EL
ELEVIDYS
Gene Therapy
ELEVIDYS
Gene Therapy
EXONDYS 51
Antisense Oligonucleotide
EX
EXONDYS 51
RNA-targeted Therapy
VYONDYS 53
Antisense Oligonucleotide
VY
VYONDYS 53
RNA-targeted Therapy
AMONDYS 45
Antisense Oligonucleotide
AM
AMONDYS 45
RNA-targeted Therapy
VILTEPSO
Antisense Oligonucleotide
SR
SRP-9001
Gene Therapy
CA
CASIMERSEN
RNA-targeted Therapy
SRP-9001
Gene Therapy
Limb-girdle muscular dystrophy programs
Gene Therapy
LI
Limb-girdle Muscular Dystrophy Programs
Gene Therapy
RNA-targeted therapeutics platform
Platform Technology
CH
Charcot-Marie-Tooth Disease Programs
Neuromuscular Therapy
類似企業
Quest Diagnostics
Public
Clinical laboratory company
Secaucus, New Jersey, United States
10,001+
Valuation $10.8B
Bio-Rad
Public
Global leader in life science research and clinical diagnostics
Hercules, California, United States
5,001-10,000
Valuation $3.2B
HCA Healthcare
Public
Leading company in the healthcare industry
Nashville, Tennessee, United States
10,001+
Valuation $75B
96 open jobs
Freenome
Series C
AI genomics company for cancer detection
South San Francisco, CA
201-500
Valuation $2.3B
33 open jobs
Caribou Biosciences
Series C
CRISPR genome editing company
Berkeley, CA
201-500
4 open jobs
Editas Medicine
Public
Genome editing company
Cambridge, Massachusetts, United States
201-500
Valuation $1.2B
ニュース＆話題
All
X
News
HN
YouTube
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target - Investing.com
Investing.com
News
·
4日前
Will Roche’s New Global Elevidys Phase 3 Trial Shift Sarepta Therapeutics' (SRPT) Gene Therapy Narrative? - simplywall.st
simplywall.st
News
·
4日前
Sarepta/ Roche Duchenne therapy to face new late-stage trial targeting EU nod - Seeking Alpha
Seeking Alpha
News
·
5日前
Roche to start new Elevidys study following setback in Europe - BioPharma Dive
BioPharma Dive
News
·
5日前
Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy - Fierce Pharma
Fierce Pharma
News
·
5日前
もっと見る (残り15件)
総閲覧数
0
応募クリック数
0
模擬応募者数
0
スクラップ
0
レビュー
3.8
48件のレビュー
ワークライフバランス
3.5
報酬
3.9
企業文化
4.0
キャリア
4.0
経営陣
3.6
76%
友人に勧める
良い点
Good work-life balance and flexible environment
Supportive team and management
Competitive compensation and benefits
改善点
Some organizational bureaucracy
Room for improvement in processes
Work-life balance varies by team
給与レンジ
47件のデータ
Director
Mid/L4
Senior/L5
Director
3件のレポート
$243,750
年収総額
基本給
$187,500
ストック
-
$240,500
$247,000
面接体験
5件の面接
難易度
2.2
/ 5
期間
2-5w
内定率
40%
体験
ポジティブ 60%
普通 20%
ネガティブ 20%
面接プロセス
1
Application Review
2
HR/Recruiter Screen
3
Technical/Phone Screen
4
Hiring Manager Interview
5
Panel/Onsite Interviews
6
Offer
連絡先・所在地